GlassScriptPhysician profile
Erin Lorraine Conniff
NPI 1437828266
$13,474.22
in general payments reported to CMS, 2019-2025
63 companies · $3,302 in 2025
The $3,302 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $786 · 2022: $2,979 · 2023: $3,258 · 2024: $3,149 · 2025: $3,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,349 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,349.13 |
| Education | $359.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,583.02 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,074.22 | 2021-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $841.39 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $739.46 | 2022-2025 | |
| Gilead Sciences, INC. | $661.48 | 2021-2025 | Trodelvy |
| Eisai INC. | $607.45 | 2021-2025 | |
| Incyte Corporation | $602.48 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $503.70 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Celgene Corporation | $479.59 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $437.98 | 2021-2025 | Adcetris, Tukysa, Padcev |
| Lilly USA, LLC | $406.56 | 2021-2025 | Verzenio, Jaypirca |
| Janssen Biotech, INC. | $397.62 | 2022-2025 | Darzalex, Tecvayli, Erleada |
| Daiichi Sankyo INC. | $350.83 | 2021-2025 | Enhertu |
| Sobi, INC | $305.33 | 2022-2025 | |
| Glaxosmithkline, LLC. | $295.77 | 2023-2025 | Ojjaara, Zejula, Jemperli |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $269.44 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $261.27 | 2021-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Alexion Pharmaceuticals, INC. | $245.57 | 2021-2025 | Ultomiris |
| Genzyme Corporation | $237.63 | 2021-2024 | |
| Abbvie INC. | $233.53 | 2021-2025 | |
| Array Biopharma INC | $224.80 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Genentech USA, INC. | $216.07 | 2022-2025 | Rozlytrek, Avastin, Gavreto |
| Beigene USA, INC. | $165.91 | 2023-2024 | Brukinsa |
| Beone Medicines USA, INC. | $147.17 | 2025 | Brukinsa |
| Morphosys, US INC. | $120.63 | 2021-2024 | Monjuvi |
| Geron Corporation | $108.04 | 2025 | Rytelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.05 | 2021-2023 | Gilotrif |
| Taiho Oncology, INC. | $99.61 | 2023-2025 | |
| Amgen INC. | $93.55 | 2021-2023 | Lumakras |
| Regeneron Healthcare Solutions, INC. | $91.96 | 2024-2025 | Libtayo |
| Alnylam Pharmaceuticals INC. | $90.58 | 2022-2023 | Onpattro, Givlaari |
| Kite Pharma, INC. | $88.19 | 2023-2025 | Yescarta |
| Puma Biotechnology, INC. | $74.02 | 2021-2025 | |
| Servier Pharmaceuticals LLC | $71.42 | 2022-2025 | |
| Adc Therapeutics America, INC. | $70.96 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $65.21 | 2022-2025 | Onivyde |
| Astellas Pharma US INC | $62.99 | 2023-2025 | Xtandi |
| Dova Pharmaceuticals | $61.91 | 2021 | |
| Jazz Pharmaceuticals INC. | $61.89 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $57.62 | 2021-2024 | Myrisk |
| Emd Serono, INC. | $55.26 | 2023-2025 | Bavencio |
| Acrotech Biopharma INC. | $53.22 | 2022 | |
| Pharmacosmos Therapeutics INC. | $51.55 | 2025 | Monoferric |
| Deciphera Pharmaceuticals INC. | $51.02 | 2021 | |
| Myovant Sciences INC. | $49.88 | 2022 | |
| Tersera Therapeutics LLC | $48.41 | 2023-2025 | Zoladex |
| Agios Pharmaceuticals, INC. | $48.22 | 2023-2024 | Pyrukynd |
| Cti Biopharma Corp. | $47.36 | 2023 | Vonjo |
| Rigel Pharmaceuticals, INC. | $47.04 | 2024 | Tavalisse, Rezlidhia |
| Pharmacyclics LLC, An Abbvie Company | $39.55 | 2022-2023 | Epkinly, Imbruvica |
| Janssen Pharmaceuticals, INC | $36.75 | 2023 | Xarelto |
| Epizyme, INC. | $36.55 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $36.43 | 2025 | Empaveli |
| Genmab U.S., INC. | $34.13 | 2025 | Epkinly |
| Aveo Pharmaceuticals, INC. | $32.78 | 2021-2023 | Fotivda |
| Recordati_rare_diseases_inc. | $31.44 | 2025 | Enjaymo |
| Pharmaessentia USA Corporation | $29.57 | 2025 | Besremi |
| Mirati Therapeutics, INC. | $28.16 | 2024 | Krazati |
| Stemline Therapeutics INC. | $27.24 | 2025 | Orserdu |
| Kyowa Kirin, INC. | $24.43 | 2024 | Poteligeo |
| Tempus Ai, INC | $23.17 | 2024 | |
| Dendreon Pharmaceuticals LLC | $18.56 | 2022 | |
| Octapharma USA, INC. | $16.60 | 2023 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Conniff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.